• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Added value of new biomarkers over the aspartate aminotransferase-to-platelet ratio index for the pr

Added value of new biomarkers over the aspartate aminotransferase-to-platelet ratio index for the pr

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户：jiangyao366
【摘 要】
：
Background:The aspartate aminotransferase-to-platelet ratio index(APRI) has the advantage of including only two inexpensive routine laboratory tests and widespread availability,but it does not directl
【作 者】
：
Seung Ha Park 
【机 构】
：
Inje University Haeundae Paik-Hospital
【出 处】
：
2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议
【发表日期】
：
2014年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:The aspartate aminotransferase-to-platelet ratio index(APRI) has the advantage of including only two inexpensive routine laboratory tests and widespread availability,but it does not directly reflect the dynamic processes of liver fibrosis.Whether the incorporation of new biomarkers into the APRI will improve the prediction of hepatitis B virus(HBV)-related fibrosis remains unknown.
其他文献
Retrospective observational study to evaluate the efficacy of entecavir in a cohort of 2,240 Korean
Background:Hepatitis B virus is endemic in Korea with greater that 90 ％infected with genotype c.Entecavir(ETV) is a potent nucleoside analogue with high genetic barrier to resistance which has been a
会议
Hepatitis B virus reactivation in HBsAg-negative and anti-HBc-positive Korean Patients with Hematolo
Background:To investigate the clinical characteristics and outcome of HBV reactivation in hepatitis B surface antigen(HBsAg)-negative and hepatitis B core antibody(anti-HBc)-positive patients with hem
会议
Efficacy of various salvage therapy for chronic hepatitis B patients who failed both initial nucleos
Background:Entecavair(ETV) 1mg monotherapy was sometimes used for the chronic hepatitis B(CHB)patients with other nucleoside resistance in the past,but now,not recommended due to sequential resistance
会议
Non-invasive assessment of liver fibrosis:Can one size fit all?
In patients with chronic liver diseases,identification of significant liver fibrosis and cirrhosis is essential for determining treatment strategies,assessing therapeutic response,and stratifying long
会议
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B vi
Background:Disruption of peripheral blood B-cell homeostasis and variation of surface receptors occur with certain infections and autoimmune diseases.However,the impact of antiviral therapy on B-cell
会议
Naturally occurring deletion/insertion mutations in hepatitis B virus core promoter confer different
Background:The core promoter(CP) of hepatitis B virus(HBV) plays a central role in viral replication and morphogenesis.The aim of this study was to characterize CP deletion(Del)/insertion(Ins) mutatio
会议
Transforming growth factor β-activated kinase 1 inhibits HBV replication and gene expression through
Background:Transforming growth factor β-activated kinase 1(TAK1) is a key mediator of innate immunity and proinflammatory signaling pathway.Previously,we found that TAK1 was involved in anti-HBV effec
会议
Incidence and determinants of HBsAg seroclearance and HBeAg seroconversion:a community-based follow-
Background:Seroclearance of HBsAg and HBeAg seroconversion are the important events in the natural history of the HBV infection.However,the spontaneous rates of HBsAg seroclearance,HBsAg seroconverion
会议
Elevated expression of chemokine CXCL13 in chronic hepatitis B patients links to immune control duri
Background:C-X-C-chemokine ligand 13(CXCL13),the ligand for C-X-C chemokine receptor type 5(CXCR5),is a major regulator of B-cell trafficking and plays an integral role in age-dependent clearance of H
会议
Predictors of the complete virologic response in na(i)ve chronic hepatitis B patients with entecavir
Background:We assessed baseline and on-treatment variables to determine predictive factors of the complete virologic response in na(i)ve chronic hepatitis B patients with entecavir therapy.
会议